Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Advances in the ability to measure chronic, active inflammation in MS using MRI and positron ...

Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...

The team, consisting of researchers from University College London (UCL) and Queen Square Analytics, analysed 634 patients ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

For the first time, UCL researchers have used AI to identify two biologically distinct forms of multiple sclerosis ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

An article published today in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.

The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

Immunization with inactivated vaccines while receiving the disease-modifying therapy natalizumab for highly active multiple sclerosis (MS) is safe and immunogenic, with no increased risk for disease ...

Patients ages 50 or older with non-active multiple sclerosis (MS) who discontinued high-efficacy therapy (HET) had a higher risk of relapse compared with those who continued HET, a matched ...